Histamine H₃ receptor ligands break ground in a remarkable plethora of therapeutic areas

Bibliography

• BOVET D, STAUB AM: Action protectrice des ethers phenolique au cours de l'intoxication histaminique. C. R. Soc. Biol. Ses. Fil. (1937) 123:547-554.
   Google Scholar
• HOUGH LB: Genomics meets histamine receptors: new subtypes, new receptors. Mol. Pharmacol. (2001) 59:415-419.
   PubMed Web of Science ®Google Scholar
• ARRANG JM, GARBARG M, SCHWARTZ JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832-837.
   PubMed Web of Science ®Google Scholar
• ARRANG JM, GARBARG M, LANCELOT JC et al.: Highly potent and selective ligands for histamine H3 receptor. Nature (1987) 327:117-123.
   PubMed Web of Science ®Google Scholar
• SCHLICKER E, KATHMANN M: Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: The Histamine H₃ Receptor; a Target for New Drugs. Leurs R, Timmerman H (Eds), Elsevier, Amsterdam, The Netherlands (1998):13-16.
   Google Scholar
• ARRANG JM, GARBARG M, SCHWARTZ JC: Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience (1985) 15:553-562.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-MIR MI, POLLARD H, MOREAU J et al.: Three histamine receptors (H1, H2, and H3) visualized in the brain of human and non-human primates. Brain Res. (1990) 526:322-327.
   PubMed Web of Science ®Google Scholar
• BERTACCINI G: Functional role of the histamine H3 receptor in peripheral tissues. In: The Histamine H₃ Receptor; a Target for New Drugs. Leurs R, Timmerman H (Eds), Elsevier, Amsterdam, The Netherlands (1998):59-111.
   Google Scholar
• LOVENBERG TW, ROLAND BL, WILSON SJ et al.: Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. (1999) 55:1101-1107.
   PubMed Web of Science ®Google Scholar
• IRELAND-DENNY L, PARIHAR AS, MILLER TR et al.: Species-related pharmacological heterogeneity of histamine H3 receptors. Eur. J. Pharmacol. (2001) 433:141-150.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, PYATI J, CHANG H, WILSON SJ, ERLANDER MG: Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. (2000) 293:771-778.
   PubMed Web of Science ®Google Scholar
• MORISSET S, ROULEAU A, GBAHOU XL et al.: High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature (2000) 408:860-864.
   PubMed Web of Science ®Google Scholar
• WIELAND K, BONGERS G, YAMAMOTO Y et al.: Constitutive activity of histamine H-3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H-3 antagonists. J. Pharmacol. Exp. Ther. (2001) 299:908-914.
   PubMed Web of Science ®Google Scholar
• GBAHOU F, ROULEAU A, MORISSET S et al.: Protean agonism at histamine H3 receptors in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2003) 100:11086-11091.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, ESTVANDER BR, MILLER TR et al.: Pharmacological classification of histamine H3 receptor agents across species is attributable to TM3 sequence differences. Inflamm. Res. (2007) (In Press).
   Google Scholar
• LIGNEAU X, MORISSET S, TARDIVEL-LACOMBE J et al.: Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. (2000) 131:1247-1250.
   PubMed Web of Science ®Google Scholar
• BAKKER RA: Histamine H3 receptor isoforms. Inflamm. Res. (2004) 53:509-516.
   PubMed Web of Science ®Google Scholar
• LEURS R, BAKKER RA, TIMMERMAN H, DE ESCH IJP: The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. (2005) 4:107-120.
   PubMed Web of Science ®Google Scholar
• CELANIRE S, WIJTMANS M, TALAGA P, LEURS R, DE ESCH IJP: Histamine H3 receptor antagonists reach out for the clinic. Drug Discov. Today (2005) 10:1613-1627.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, FOX GB, COWART MD: Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv. (2006) 6:77-78.
   PubMed Web of Science ®Google Scholar
• LETAVIC MA, BARBIER AJ, DVORAK CA, CARRUTHERS NI: Recent medicinal chemistry of the histamine H3 receptor. Prog. Med. Chem. (2006) 44:181-206.
   PubMedGoogle Scholar
• BONAVENTURE P, LETAVIC M, DUGOVIC C et al.: Histamine H3 receptor antagonists: from target identification to drug leads. Biochem. Pharmacol. (2007) 73:1084-1096.
   PubMed Web of Science ®Google Scholar
• DE ESCH IJP, BELZAR KJ: Histamine H3 receptor agonists. Mini Rev. Med. Chem. (2004) 4:955-963.
   PubMed Web of Science ®Google Scholar
• ODA T, MORIKAWA N, SAITO Y, MASUHO Y, MATSUMOTO S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. (2000) 275:36781-36786.
   PubMed Web of Science ®Google Scholar
• LIM HD, RIJN RMV, LING P et al.: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. (2005) 314:1310-1321.
   PubMed Web of Science ®Google Scholar
• KITBUNNADAJ R, ZUIDERVELD OP, CHRISTOPHE B et al.: Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H3 receptor agonist. J. Med. Chem. (2004) 47:2414-2417.
   PubMed Web of Science ®Google Scholar
• KITBUNNADAJ R, HASHIMOTO T, POLI E et al.: N-Substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J. Med. Chem. (2005) 48:2100-2107.
   PubMed Web of Science ®Google Scholar
• MCLEOD RL, ASLANIAN R, PRADO MD et al.: Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J. Pharmacol. Exp. Ther. (1998) 287:43-50.
   PubMed Web of Science ®Google Scholar
• ROULEAU A, GARBARG M, LIGNEAU X et al.: Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug. J. Pharmacol. Exp. Ther. (1997) 281:1085-1094.
   PubMed Web of Science ®Google Scholar
• MATSUBARA T, MOSKOWITZ MA, HUANG Z: UK-14,304, R(-)-α-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. Eur. J. Pharmacol. (1992) 224:145-150.
   PubMed Web of Science ®Google Scholar
• O'CONNOR BJ, LECOMTE JM, BARNES PJ: Effect of an inhaled histamine H3-receptor agonist on airway responses to sodium metabisulphite in asthma. Br. J. Clin. Pharmacol. (1993) 35:55-57.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JC: The histamine H3 receptor: from molecular pharmacology to clinical applications. Abstr. 2nd Int. Symp. Mol. Med. (2002).
   Google Scholar
• ASLANIAN R, LEE G, IYER RV et al.: An asymmetric synthesis of the novel H3 agonist (+)-(3R,4R)-3-(4-imidazolyl)-4-methylpyrrolidine dihydrochloride (Sch 50971). Tetrahedron Asymmetry (2000) 11:3867-3871.
   Web of Science ®Google Scholar
• MILLáN-GUERRERO RO, PINEDA-LUCATERO AG, HERNANDEZ BT, TENE CE, PACHECO MF: N-α-Methylhistamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. Headache (2003) 43:389-394.
   PubMed Web of Science ®Google Scholar
• MILLáN-GUERRERO RO, ISAIS-MILLáN R, BENJAMìN T-H, TENE CE: N-α-Methylhistamine safety and efficacy in migraine prophylaxis: Phase III study. Can. J. Neurol. Sci. (2006) 33:195-199.
   PubMed Web of Science ®Google Scholar
• LIM HD, SMITS RA, LEURS R, DE ESCH IJP: The emerging role of the histamine H-4 receptor in anti-inflammatory therapy. Curr. Top. Med. Chem. (2006) 6:1365-1373.
   PubMed Web of Science ®Google Scholar
• CANNON KE, NALWALK JW, STADEL R et al.: Activation of spinal histamine H3 receptors inhibits mechanical nociception. Eur. J. Pharmacol. (2003) 470:139-147.
   PubMed Web of Science ®Google Scholar
• CANNON KE, HOUGH LB: Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H3 receptors. J. Pain (2005) 6:193-200.
   PubMed Web of Science ®Google Scholar
• CANNON KE, CHAZOT PL, HANN V et al.: Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain (2007) 129(1-2):76-92.
   PubMed Web of Science ®Google Scholar
• FARZIN D, NOSRATI F: Modification of formalin-induced nociception by different histamine receptor agonists and antagonists. Eur. Neuropsychopharmacol. (2007) 17:122-128.
   PubMed Web of Science ®Google Scholar
• POVEDA R, FERNáNDEZ-DUEÑAS V, FERNáNDEZ A et al.: Synergistic interaction between fentanyl and the histamine H3 receptor agonist R-α-methylhistamine, on the inhibition of nociception and plasma extravasation in mice. Eur. J. Pharmacol. (2006) 541:53-56.
   PubMed Web of Science ®Google Scholar
• LEVI R, SMITH NC: Histamine H3-receptors: a new frontier in myocardial ischemia. J. Pharmacol. Exp. Ther. (2000) 292:825-830.
   PubMed Web of Science ®Google Scholar
• SEYEDI N, MACKINS CJ, MACHIDA T et al.: Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase A activity mediates a reduction in intracellular calcium. J. Pharmacol. Exp. Ther. (2005) 312:272-280.
   PubMed Web of Science ®Google Scholar
• LEVI R, SEYEDI N, SCHAEFER U et al.: Histamine H3-receptor signaling in cardiac sympathetic nerves: identification of a novel MAPK-PLA2-COX-PGE2-EP3R pathway. Biochem. Pharmacol. (2007) 73:1146-1156.
   PubMed Web of Science ®Google Scholar
• MACKINS CJ, LEVI R: Therapeutic potential of H3-receptor agonists in myocardial infarction. Expert Opin. Investig. Drugs (2000) 9(11):2537-2542.
   PubMed Web of Science ®Google Scholar
• LIN JS: Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med. Rev. (2000) 4:471-503.
   PubMed Web of Science ®Google Scholar
• LIN JS, SAKAI K, VANNI-MERCER G et al.: Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3 receptor ligands in the cat. Brain Res. (1990) 523:325-330.
   PubMed Web of Science ®Google Scholar
• PARMENTIER R, ANACLET C, GUHENNEC C et al.: The brain H(3)-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem. Pharmacol. (2007) 73:1157-1171.
   PubMed Web of Science ®Google Scholar
• LAMBERTY Y, MARGINEANU DG, DASSESSE D, KLITGAARD H: H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol. Res. (2003) 48:193-198.
   PubMed Web of Science ®Google Scholar
• HUANG Z-L, MOCHIZUKI T, QU W-M et al.: Altered sleep–wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc. Natl. Acad. Sci. USA (2006) 103:4687-4692.
   PubMed Web of Science ®Google Scholar
• APODACA R, ADVORAK C, XIAO W et al.: A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. J. Med. Chem. (2003) 46:3938-3944.
   PubMed Web of Science ®Google Scholar
• BARBIER AJ, BERRIDGE C, DUGOVIC C et al.: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br. J. Pharmacol. (2004) 143:649-661.
   PubMed Web of Science ®Google Scholar
• DVORAK CA, APODACA R, BARBIER AJ et al.: 4-Phenoxypiperidines: potent, ponformationally restricted, non-imidazole histamine H3 antagonists. J. Med. Chem. (2005) 48:2229-2238.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS NI: Conformational restriction in the design of diamine-based human histamine H3 receptor antagonists. 34th Meeting of European Histamine Research Society, Bled, Slovenia (11 – 14 May 2005).
   Google Scholar
• FUJIKI N, YOSHINO F, LOVENBERG TW, NISHINO S: Wake promoting effects of non-imidazolin histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice (2006 Sleep Research Society Meeting). Sleep (2006) 29(Suppl.):0678 (Abstract).
   Google Scholar
• KEITH JM, GOMEZ LA, LETAVIC MA et al.: Dual serotonin transporter/histamine H3 ligands: optimization of the H3 pharmacophore. Bioorg. Med. Chem. Lett. (2007) 17:702-706.
   PubMed Web of Science ®Google Scholar
• LETAVIC MA, KEITH JM, JABLONOWSKI JA et al.: Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. (2007) 17:1047-1051.
   PubMed Web of Science ®Google Scholar
• LETAVIC MA, KEITH JM, LY KS et al.: Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors. Bioorg. Med. Chem. Lett. (2007) 17:2566-2569.
   PubMed Web of Science ®Google Scholar
• KEITH JM, GOMEZ LA, WOLIN RL et al.: Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett. (2007) 17:2603-2607.
   PubMed Web of Science ®Google Scholar
• DEAN D, APPS J, BAMFORD M et al.: A novel series of histamine H3 antagonists. Abstracts from XIXth International Symposium on Medicinal Chemistry, Istanbul, Turkey (2006):P195.
   Google Scholar
• WILSON D: The discovery of a novel series of potent, orally active histamine H3 receptor antagonists. RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK (2005):XIII (Abstract).
   Google Scholar
• GIOVANNINI MG, BARTOLINI L, BACCIOTTINI L, GRECO L, BLANDINA P: Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav. Brain Res. (1999) 104:147-155.
   PubMed Web of Science ®Google Scholar
• MEGURO K, YANAI K, SAKAI N et al.: Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol. Biochem. Behav. (1995) 50:321-325.
   PubMed Web of Science ®Google Scholar
• PRAST H, ARGYRIOU A, PHILIPPU A: Histaminergic neurons facilitate social memory in rats. Brain Res. (1996) 734:316-318.
   PubMed Web of Science ®Google Scholar
• AKHTAR M, DEVI PU, ALI A, PILLAI KK, VOHORA D: Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundam. Clin. Pharmacol. (2006) 20:373-378.
   PubMed Web of Science ®Google Scholar
• JIA FY, KATO M, DAI HM et al.: Effects of histamine H3 antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology (2006) 50:404-411.
   PubMed Web of Science ®Google Scholar
• PASSANI MB, BACCIOTTINI L, MANNAIONI PF, BLANDINA P: Central histaminergic system and cognition. Neurosci. Biobehav. Rev. (2000) 24:107-113.
   PubMed Web of Science ®Google Scholar
• LIU HQ, KERDESKY FA, BLACK LA et al.: An efficient multigram synthesis of the potent histamine H-3 antagonist GT-2331 and the reassessment of the absolute configuration. J. Org. Chem. (2004) 69:192-194.
   PubMed Web of Science ®Google Scholar
• ITO S, YOSHIMOTO R, MIYAMOTO Y et al.: Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. Eur. J. Pharmacol. (2006) 529:40-46.
   PubMed Web of Science ®Google Scholar
• MEDHURST AD, ATKINS AR, BERESFORD IJ et al.: GSK189254 – a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. (2007) 321(3):1032-1045.
   PubMed Web of Science ®Google Scholar
• MEDHURST AD, BRIGGS MA, BRUTON G et al.: Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem. Pharmacol. (2007) 73:1182-1194.
   PubMed Web of Science ®Google Scholar
• KU Y-Y, PU Y-M, GRIEME T et al.: An efficient and convergent synthesis of the potent and selective H3 antagonist ABT-239. Tetrahedron (2006) 62:4584-4589.
   Web of Science ®Google Scholar
• FAGHIH R, DWIGHT W, VASUDEVAN A et al.: Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett. (2002) 12:3077-3079.
   PubMed Web of Science ®Google Scholar
• COWART M, PRATT JK, STEWART AO et al.: A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. (2004) 14:689-693.
   PubMed Web of Science ®Google Scholar
• COWART M, FAGHIH R, CURTIS MP et al.: 4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. (2005) 48:38-55.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, FOX GB, KRUEGER KM et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J. Pharmacol. Exp. Ther. (2005) 313:165-175.
   PubMed Web of Science ®Google Scholar
• FOX GB, ESBENSHADE TA, PAN JB et al.: Pharmacological properties of ABT-239[4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. (2005) 313:176-190.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA: The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem. Pharmacol. (2006) 71:1103-1113.
   PubMed Web of Science ®Google Scholar
• COWART M, GFESSER GA, BROWMAN KE et al.: Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem. Pharmacol. (2007) 73:1243-1255.
   PubMed Web of Science ®Google Scholar
• BLACK LA, NERSESIAN DL, SHARMA P et al.: 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. Bioorg. Med. Chem. Lett. (2007) 17:1443-1446.
   PubMed Web of Science ®Google Scholar
• STARK H, HULS A, LIGNEAU X et al.: Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure. Archiv. Der Pharmazie (1998) 331:211-218.
   Google Scholar
• ONODERA K, MIYAZAKI S, IMAIZUMI M, STARK H, SCHUNACK W: Improvement by FUB 181, a novel histamine H3-receptor antagonist, of learning and memory in the elevated plus-maze test in mice. N-S Arch. Pharmacol. (1998) 357:508-513.
   PubMed Web of Science ®Google Scholar
• MEIER G, APELT J, REICHERT U et al.: Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. J. Pharm. Sci. (2001) 13:249-259.
   PubMed Web of Science ®Google Scholar
• LIGNEAU X, PERRIN D, LANDAIS L et al.: BF2.649, a non-imidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. (2007) 320:365-375.
   PubMed Web of Science ®Google Scholar
• LIGNEAU X, LANDAIS L, PERRIN D et al.: Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem. Pharmacol. (2007) 73:1215-1224.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS NI: (1-[4-(3-Piperidin-1-ylpropoxy)benzyl] piperidine): a template for the design of potent and selective non-imidazole histamine H3 receptor antagonists. Abstracts from European Histamine Research Society, Dusseldorf/Koln, Germany (2004):31.
   Google Scholar
• JESUDASON CD, BEAVERS LS, CRAMER JW et al.: Synthesis and SAR of novel histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16:3415-3418.
   PubMed Web of Science ®Google Scholar
• JESUDASON CD, BEAVERS LS, CRAMER JW et al.: (3-Piperidin-1-yl-propoxy)-tetrahydroisoquinolines and tetra-hydroazepines: a novel series of selective histamine H3 receptor antagonists. Abstracts from European Histamine Research Society, Delphi, Greece (2006):P11.
   Google Scholar
• FOX GB, PAN JB, ESBENSHADE TA et al.: Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model. Pharmacol. Biochem. Behav. (2002) 72:741-750.
   Google Scholar
• YOSHIMOTO R, MIYAMOTO Y, TAKAHASHI K et al.: Impaired drinking response in histamine H3 receptor knockout mice following dehydration or angiotensin-II challenge. Pharmacol. Biochem. Behav. (2006) 84:504-510.
   PubMed Web of Science ®Google Scholar
• HEMRICK-LUECKE SK, THOMPSON LK, GLEASON SD et al.: Behavioral and neurochemical effects of two novel histamine H3 receptor antagonists: TISQ and THBAZ. 2005 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington DC, USA (2005):567.5 (Program).
   Google Scholar
• GAMMIE SC, DAWSON VL, NELSON RJ: Influence of nitric oxide on neuroendocrine function and behavior. In: Nitric Oxide. Ignarro LJ (Ed.), Academic Press, San Diego, USA (2000):429-438.
   Web of Science ®Google Scholar
• BERTINARIA M, STILO AD, TOSCO P et al.: [3-(1H-Imidazol-4-yl)propyl]guanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. Bioorg. Med. Chem. (2003) 11:1197-1205.
   PubMed Web of Science ®Google Scholar
• TOSCO P, BERTINARIA M, STILO AD et al.: Non-imidazole histamine NO-donor H3-antagonists. Il Farmaco (2005) 60:507-512.
   PubMedGoogle Scholar
• GRASSMANN S, APELT J, SIPPL W et al.: Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorg. Med. Chem. (2003) 11:2163-2174.
   PubMed Web of Science ®Google Scholar
• PETROIANU G, ARAFAT K, SASSE BC, STARK H: Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie (2006) 61:179-182.
   PubMed Web of Science ®Google Scholar
• CLADER JW, WANG Y: Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr. Pharm. Des. (2005) 11:3353-3361.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JC, ARRANG JM, GARBARG M, POLLARD H, RUAT M: Histaminergic transmission in the mammalian brain. Physiol. Rev. (1991) 71:1-51.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BRUNE ME: Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin. Investig. Drugs (2005) 14(3):223-241.
   Web of Science ®Google Scholar
• TOKITA S, TAKAHASHI K, KOTANI H: Recent advances in molecular pharmacology of the histamine systems: Physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharmacol. Sci. (2006) 101:12-18.
   PubMed Web of Science ®Google Scholar
• YATES SL, PAWLOWSKI GP, BABU JS et al.: Inverse agonists of the histamine-3 receptor as appetit suppressants. Abstracts from 225th American Chemical Society National Meeting, New Orleans, USA (2003):P2.
   Google Scholar
• FAGHIH R, DWIGHT W, BLACK L et al.: Structure-activity relationships of non-imidazole H-3 receptor ligands. Part 2: binding preference for D-amino acids motifs. Bioorg. Med. Chem. Lett. (2002) 12:2035-2037.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, KRUEGER KM, MILLER TR et al.: Two novel and selective nonimidazole histamine H-3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. (2003) 305:887-896.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BENNANI YL, BUSH EN et al.: Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur. J. Pharmacol. (2004) 487:183-197.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, DIEHL MS, FAGHIH R et al.: In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin. Pharmacol. Toxicol. (2004) 95:144-152.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, DIEHL MS, FEY TA et al.: Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Abstracts from European Histamine Research Society, Dusseldorf/Koln, Germany (2004):54.
   Google Scholar
• ZARAGOZA F, STEPHENSEN H, KNUDSEN SM et al.: 1-Alkyl-4-acylpiperazines as a new class of imidazole-free histamine H3 receptor antagonists. J. Med. Chem. (2004) 47:2833-2838.
   PubMed Web of Science ®Google Scholar
• MALMLOF K, ZARAGOZA F, GOLOZOUBOVA V et al.: Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int. J. Obesity (2005) 29:1402-1412.
   Web of Science ®Google Scholar
• PESCHKE B, BAK S, HOHLWEG R et al.: Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists. Bioorg. Med. Chem. (2004) 12:2603-2616.
   PubMed Web of Science ®Google Scholar
• MALMLÖF K, GOLOZOUBOVA V, PESCHKE B et al.: Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring) (2006) 14:2154-2162.
   PubMed Web of Science ®Google Scholar
• MALMLÖF K, HASTRUP S, WULFF BS et al.: Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species. Biochem. Pharmacol. (2007) 73:1237-1242.
   PubMed Web of Science ®Google Scholar
• LAU JF, JEPPESEN CB, RIMVALL K, HOHLWEG R: Ureas with histamine H3-antagonist receptor activity – a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. (2006) 16:5303-5308.
   PubMed Web of Science ®Google Scholar
• PESCHKE B, BAK S, HOHLWEG R et al.: Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor. Bioorg. Med. Chem. Lett. (2006) 16:3162-3165.
   PubMed Web of Science ®Google Scholar
• FREICHEL C, ARTHUR SG-M, HERTEL C et al.: Histamine 3 receptor inverse agonists for the treatment of obesity. Biological and chemical challenges. Abstracts from European Histamine Research Society, Delphi, Greece (2006):P8.
   Google Scholar
• YOSHIMOTO R, MIYAMOTO Y, SHIMAMURA K et al.: Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA (2006) 103:13866-13871.
   PubMed Web of Science ®Google Scholar
• ZUO Y, PERKINS NM, TRACEY DJ, GECZY CL: Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain (2003) 105:467-479.
   PubMed Web of Science ®Google Scholar
• MCLEOD RL, MINGO GG, HERCZKU C et al.: Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. (1999) 13:391-399.
   PubMedGoogle Scholar
• MCLEOD RL, MINGO GG, KREUTNER W, HEY JA: Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. Life Sci. (2005) 76:1787-1794.
   PubMed Web of Science ®Google Scholar
• VARTY LM, GUSTAFSON E, LAVERTY M, HEY JA: Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur. J. Pharmacol. (2004) 484:83-89.
   PubMed Web of Science ®Google Scholar
• TAYLOR-CLARK T, SODHA R, WARNER B, FOREMAN J: Histamine receptors that influence blockage of the normal human nasal airway. Br. J. Pharmacol. (2005) 144:867-874.
   PubMed Web of Science ®Google Scholar
• ASLANIAN R, BROWN JE, SHIH NY et al.: 4-[(1H-Imidazol-4-yl)methyl]benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor. Bioorg. Med. Chem. Lett. (1998) 8:2263-2268.
   PubMed Web of Science ®Google Scholar
• ASLANIAN R, MUTAHI MW, SHIH NY et al.: Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template. Bioorg. Med. Chem. Lett. (2002) 12:937-941.
   PubMed Web of Science ®Google Scholar
• DE ESCH IJP, MILLS JEJ, PERKINS TDJ et al.: Development of a pharmacophore model for histamine H-3 receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem. (2001) 44:1666-1674.
   PubMed Web of Science ®Google Scholar
• MCLEOD RL, RIZZO CA, WEST RE et al.: Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N ′-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). J. Pharmacol. Exp. Ther. (2003) 305:1037-1044.
   PubMed Web of Science ®Google Scholar
• YANG R, HEY JA, ASLANIAN R, RIZZO CA: Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology (2002) 66:128-135.
   PubMed Web of Science ®Google Scholar
• VACCARO WD, SHER R, BERLIN M et al.: Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg. Med. Chem. Lett. (2006) 16:395-399.
   PubMed Web of Science ®Google Scholar
• BERLIN M, TING PC, VACCARO WD et al.: Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16:989-994.
   PubMed Web of Science ®Google Scholar
• ASLANIAN R, ZHU X, TOM W et al.: Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. Abstracts from 232nd American Chemical Society National Meeting, San Fransisco, USA (2006):MEDI501.
   Google Scholar
• ASLANIAN R, MUTAHI MW, SHIH NY et al.: Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg. Med. Chem. Lett. (2003) 13:1959-1961.
   PubMed Web of Science ®Google Scholar
• MARTIN FC, LE AT, HANDFORTH A: Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov. Disord. (2005) 20:298-305.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BITNER RS, KRUEGER KM et al.: Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflamm. Res. (2006) 55:S42-S44.
   Google Scholar
• KOYAMA M, SEYEDI N, FUNG-LEUNG W-P, LOVENBERG TW, LEVI R: Norepinephrine release from the ischemic heart is greatly enhanced in mice lacking histamine H3 receptors. Mol. Pharmacol. (2003) 63:378-382.
   PubMed Web of Science ®Google Scholar
• FOX GB, PAN JB, RADEK RJ et al.: Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. (2003) 305:897-908.
   PubMed Web of Science ®Google Scholar
• PAN JB, YAO BB, MILLER TR et al.: Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci. (2006) 79:1366-1379.
   PubMed Web of Science ®Google Scholar
• ZHANG M, BALLARD ME, PAN LP et al.: Lack of cataleptogenic potentiation with non-imidazole H-3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H-3 receptor antagonists and antipsychotic drugs. Brain Res. (2005) 1045:142-149.
   PubMed Web of Science ®Google Scholar